Compare Stocks: VIR, RYTM, SRRK, and CGON

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.35 +0.5%	$73.79	$32.57 ▼ $80.97	$6.38B	0.24	631,035 shs	759,833 shs
RYTM Rhythm Pharmaceuticals	$104.71 +2.5%	$108.65	$74.50 ▼ $122.20	$7.00B	1.97	426,877 shs	573,720 shs
SRRK Scholar Rock	$55.41 -0.5%	$53.56	$27.07 ▼ $61.76	$6.78B	0.67	1.08 million shs	921,666 shs
VIR Vir Biotechnology	$10.62 +0.4%	$9.83	$4.75 ▼ $11.94	$1.79B	1.63	1.87 million shs	2.08 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+0.49%	-3.11%	-6.03%	+21.47%	+115.14%
RYTM Rhythm Pharmaceuticals	+2.46%	+1.92%	-10.96%	+18.48%	+4.43%
SRRK Scholar Rock	-0.47%	+0.14%	+2.95%	+25.42%	+77.37%
VIR Vir Biotechnology	+0.38%	-6.76%	+18.53%	+23.34%	+107.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$72.35 +0.5%	$73.79	$32.57 ▼ $80.97	$6.38B	0.24	631,035 shs	759,833 shs
RYTM Rhythm Pharmaceuticals	$104.71 +2.5%	$108.65	$74.50 ▼ $122.20	$7.00B	1.97	426,877 shs	573,720 shs
SRRK Scholar Rock	$55.41 -0.5%	$53.56	$27.07 ▼ $61.76	$6.78B	0.67	1.08 million shs	921,666 shs
VIR Vir Biotechnology	$10.62 +0.4%	$9.83	$4.75 ▼ $11.94	$1.79B	1.63	1.87 million shs	2.08 million shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	+0.49%	-3.11%	-6.03%	+21.47%	+115.14%
RYTM Rhythm Pharmaceuticals	+2.46%	+1.92%	-10.96%	+18.48%	+4.43%
SRRK Scholar Rock	-0.47%	+0.14%	+2.95%	+25.42%	+77.37%
VIR Vir Biotechnology	+0.38%	-6.76%	+18.53%	+23.34%	+107.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	2.73	Moderate Buy	$87.78	21.32% Upside
RYTM Rhythm Pharmaceuticals	2.74	Moderate Buy	$141.12	34.77% Upside
SRRK Scholar Rock	3.06	Buy	$58.77	6.06% Upside
VIR Vir Biotechnology	2.88	Moderate Buy	$21.57	103.12% Upside

Current Analyst Ratings Breakdown

Latest VIR, RYTM, SRRK, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/10/2026	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/8/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/8/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/28/2026	RYTM Rhythm Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold	$120.00
8/21/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$64.00
8/13/2026	SRRK Scholar Rock	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$56.00 ➝ $63.00
8/10/2026	VIR Vir Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	SRRK Scholar Rock	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$65.00
8/10/2026	SRRK Scholar Rock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$58.00
8/7/2026	SRRK Scholar Rock	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$76.00
8/7/2026	SRRK Scholar Rock	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$58.00 ➝ $60.00

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$6.23M	1,029.72	N/A	N/A	$9.33 per share	7.75
RYTM Rhythm Pharmaceuticals	$189.76M	37.82	N/A	N/A	$2.08 per share	50.34
SRRK Scholar Rock	N/A	N/A	N/A	N/A	$2.41 per share	N/A
VIR Vir Biotechnology	$302.59M	5.94	N/A	N/A	$5.50 per share	1.93

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$160.99M	-$2.69	N/A	N/A	N/A	-3,602.68%	-25.20%	-23.98%	11/13/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	11/3/2026 (Estimated)
SRRK Scholar Rock	-$377.94M	-$3.45	N/A	N/A	N/A	N/A	-160.19%	-87.18%	11/13/2026 (Estimated)
VIR Vir Biotechnology	-$437.99M	-$1.86	N/A	N/A	N/A	-638.88%	-29.99%	-23.62%	11/4/2026 (Estimated)

Latest VIR, RYTM, SRRK, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	CGON CG Oncology	-$0.6642	-$0.90	-$0.2359	-$0.90	$0.36 million	$1.16 million
8/6/2026	Q2 2026	SRRK Scholar Rock	-$0.8405	-$0.84	+$0.0005	-$0.84	$3.33 million	N/A
8/5/2026	Q2 2026	VIR Vir Biotechnology	$0.3326	$0.47	+$0.1374	$0.47	$135.88 million	$238.95 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SRRK Scholar Rock	N/A	N/A	N/A	N/A	N/A
VIR Vir Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	22.22	22.20
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
SRRK Scholar Rock	0.77	7.02	7.02
VIR Vir Biotechnology	N/A	6.04	6.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
RYTM Rhythm Pharmaceuticals	N/A
SRRK Scholar Rock	91.08%
VIR Vir Biotechnology	65.32%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	4.80%
RYTM Rhythm Pharmaceuticals	5.90%
SRRK Scholar Rock	10.30%
VIR Vir Biotechnology	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	142	88.64 million	84.39 million	Optionable
RYTM Rhythm Pharmaceuticals	414	68.53 million	64.49 million	Optionable
SRRK Scholar Rock	289	121.79 million	109.24 million	Optionable
VIR Vir Biotechnology	367	169.22 million	164.31 million	Optionable

VIR, RYTM, SRRK, and CGON Headlines

Recent News About These Companies

Vir Biotechnology, Inc. (NASDAQ:VIR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 10 at 3:44 AM | americanbankingnews.com

Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR

September 6, 2026 | marketbeat.com

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages

September 5, 2026 | marketbeat.com

Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR

September 4, 2026 | marketbeat.com

Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR

September 3, 2026 | marketbeat.com

Corient Private Wealth LP Invests $3.17 Million in Vir Biotechnology, Inc. $VIR

September 2, 2026 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week High - Should You Buy?

September 2, 2026 | marketbeat.com

Vir Biotechnology (NASDAQ:VIR) Trading 4.8% Higher - Here's What Happened

September 1, 2026 | marketbeat.com

Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

August 31, 2026 | businesswire.com

Deutsche Bank AG Acquires Shares of 134,258 Vir Biotechnology, Inc. $VIR

August 30, 2026 | marketbeat.com

BlackRock Inc. Purchases New Position in Vir Biotechnology, Inc. $VIR

August 28, 2026 | marketbeat.com

Vir Biotechnology, Inc. (VIR) Stock Price, News, Quote & History - Yahoo Finance

August 28, 2026 | finance.yahoo.com

Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR

August 26, 2026 | marketbeat.com

ARCH Venture Management LLC Invests $129.35 Billion in Vir Biotechnology, Inc. $VIR

August 26, 2026 | marketbeat.com

Vir Biotechnology climbs 9% amid post-earnings uptrend

August 25, 2026 | seekingalpha.com

Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1% - Time to Buy?

August 25, 2026 | marketbeat.com

Parkman Healthcare Partners LLC Takes Position in Vir Biotechnology, Inc. $VIR

August 25, 2026 | marketbeat.com

Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum

August 20, 2026 | theglobeandmail.com

Vir Biotechnology’s HBV Combo Vaccine Study Reaches Completion, Setting Up Key Pipeline Catalyst

August 19, 2026 | tipranks.com

Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript

August 12, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VIR, RYTM, SRRK, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

$72.35 +0.35 (+0.49%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$72.31 -0.04 (-0.06%)

As of 09/11/2026 07:30 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$104.71 +2.51 (+2.46%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$104.76 +0.06 (+0.05%)

As of 09/11/2026 07:30 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Scholar Rock NASDAQ:SRRK

$55.41 -0.26 (-0.47%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$61.95 +6.54 (+11.80%)

As of 09/11/2026 07:59 PM Eastern

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Vir Biotechnology NASDAQ:VIR

$10.62 +0.04 (+0.38%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$10.54 -0.07 (-0.71%)

As of 09/11/2026 07:30 PM Eastern

Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIR, RYTM, SRRK, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIR, RYTM, SRRK, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIR, RYTM, SRRK, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIR, RYTM, SRRK, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Rhythm Pharmaceuticals NASDAQ:RYTM

Scholar Rock NASDAQ:SRRK

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VIR, RYTM, SRRK, and CGON Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VIR, RYTM, SRRK, and CGON Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VIR, RYTM, SRRK, and CGON Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

VIR, RYTM, SRRK, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

Rhythm Pharmaceuticals NASDAQ:RYTM

Scholar Rock NASDAQ:SRRK

Vir Biotechnology NASDAQ:VIR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools